Although several biomarkers appear to be shared across sJIA and AOSD, particularly ferritin, S100 proteins, and IL-18 [2], additional studies are needed to assess the robustness of these indicators and the potential benefits of including them in clinical trials to assess responses to new therapies as well as in everyday clinical practice. Here, IL18 is linked to adult-onset Still disease.